<DOC>
	<DOC>NCT00195377</DOC>
	<brief_summary>The purpose of this study is to assess the safety of etanercept in patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) or psoriatic arthritis (PsA) in Spain</brief_summary>
	<brief_title>Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>RA or PsA in whom DMARDs/antiTNF antibodies/anti IL1 has been insufficient or inappropriate Children from 4 to 17 years old with JIA polyarticular Clinically significant abnormal screening lab values Patients who are planning to undergo elective surgery during the study period. Other current autoimmune connective tissue diseases</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>